Send to

Choose Destination
Vet Ther. 2006 Summer;7(2):127-40.

Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.

Author information

Merial Limited, 3239 Satellite Blvd, Duluth, GA 30096, USA.


A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P < .05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P < .05) at each scoring.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center